August 27th, 2026

Lisraya is the first FDA-approved oral treatment option for patients with dermatomyositis, addressing the high unmet need for this rare disease. Silver Spring, MD / CRWE PRESS RELEASE / August 27, 2026 - The U.S. Food and Drug Administration . Read more

August 04th, 2023

Mesoblast Limited (Nasdaq: MESO) has announced the receipt of a comprehensive response from the US Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) resubmission for remestemcel-L. The FDA's response stipulates the . Read more

July 05th, 2023

Romeo Power, Inc., a subsidiary of Nikola Corporation (Nasdaq: NKLA), transferred ownership of its tangible and intangible assets to SG Service Co., LLC, acting as Assignee for the Benefit of Creditors of Romeo, as per a regulatory filing with the SE. Read more

June 16th, 2023

Nikola Corporation (Nasdaq: NKLA) has provided a progress update on its business optimization efforts, which aim to streamline operations and reduce cash spend. As part of these initiatives, the company conducted a thorough review of its organization. Read more

June 16th, 2023

In a regulatory filing with the SEC, Nikola Corporation (Nasdaq: NKLA) has responded to a recent social media post by its former CEO, Trevor Milton, stating that it misstates the facts. According to the company, since Milton's departure in September . Read more

May 10th, 2023

Celsius Holdings, Inc. (Nasdaq: CELH) has received a notable upgrade from BofA Securities, shifting its rating from Neutral to Buy. Alongside the upgrade, BofA Securities has raised the price target for CELH to $125 from $98. This positive developmen. Read more